DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for geleophysic dysplasia — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGeleophysic dysplasia maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for geleophysic dysplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibrillin 1 (FBN1) — FBN1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1UZK · 1.35 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Geleophysic dysplasia is an extremely rare acromelic skeletal dysplasia, with fewer than 40 patients described worldwide as of 2013. Three Saudi sisters with autosomal recessive disease showed different levels of severity of cardiac involvement in a 2013 report. Two boys reported in 1997 had facial anomalies, small hands and feet, joint contractures, thick skin, an unusual tiptoe gait, and lysosome-like inclusions in hepatocytes, compatible with the diagnosis. One of those boys also had liver fibrosis and fatty degeneration. Neither had short stature or progressive cardiac valvular disease, and their facial appearance was different from typical cases. The authors concluded that a mild form of geleophysic dysplasia exists and that the disorder has a broader clinical spectrum than initially suspected.
A 2021 study described three Russian female patients with acromelic dysplasias caused by three missense mutations in the FBN1 gene. One patient was diagnosed with geleophysic dysplasia, and two with acromicric dysplasia. All identified mutations were localised in exons encoding the fifth domain of fibrillin-1, which has homology with transforming growth factor-beta. The authors reported that the most severe clinical manifestations occurred in patients with a mutation that replaces cysteine with arginine at position 1736 of the polypeptide chain (c.5206T>C). The c.5284G>A (p.Gly1762Ser) mutation led to moderate manifestations of acromicric dysplasia. A previously undescribed substitution, c.5177G>A (p.Gly1726Asp), and another previously described mutation at the same codon replacing glutamine with valine, caused a less pronounced phenotype of acromicric dysplasia.
No drug treatment is mentioned in any of these abstracts. There are no data on survival, response rates, or sample sizes beyond the individual case descriptions. The natural history is variable: some patients have severe cardiac involvement, others do not. What is still missing is any systematic natural history study with enough patients to define progression, any biomarker for cardiac or hepatic disease, any trial design for a potential therapy, and any funding for such work. Patient stratification by genotype is not yet possible beyond the few mutations described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cardiology in the Young · 2013 · 10 citations
Cardiac involvement in geleophysic dysplasia in three siblings of a Saudi family
AbstractGeleophysic dysplasia is an extremely rare acromelic skeletal dysplasia resembling lysosomal storage disease. It is characterised by characteristic facial phenotype, short stature, micromelia, joint contracture, and early cardiac valvular involvement. It has been described worldwide in <40 patients. Herein, we describe the cardiac features in three Saudi sisters with proved autosomal recessive geleophysic dysplasia who showed different levels of severity of their cardiac involvement.
Pediatric Traumatology Orthopaedics and Reconstructive Surgery · 2021 · 0 citations · open access
Clinical and genetic characteristics of rare variants of acromelic skeletal dysplasias caused by mutations in the <i>FBN1</i> gene
AbstractBACKGROUND: Geleophysic dysplasia and acromicric dysplasia are rare hereditary diseases characterized by dwarfism and dysplastic skeletal features. In the literature, only a few cases of geleophysic dysplasia and acromicric dysplasia caused by mutations in the FBN1 gene are described. CLINICAL CASES: A description of the clinical and genetic characteristics of three female patients with acromelic dysplasias caused by three types of missense mutations in the FBN1 gene is presented. In two patients, on the basis of clinical manifestations and radiographic examination, acromicric dysplasia, and in one patient geleophysic dysplasia were diagnosed. It was shown that all identified mutations were localized in exons of the FBN1 gene encoding the amino acid sequence of the fifth domain, which has homology with transforming growth factor-beta. DISCUSSION: We have analyzed the clinical and genetic correlations to confirm the previously stated hypothesis about the occurrence of a severe phenotype of geleophysic dysplasia in patients with the c.5206T C mutation. This mutation is characterized by the replacement of cysteine by arginine in the position of the polypeptide chain leading to moderate clinical manifestations of acromicric dysplasia in patients with the c.5284 G A (p. Gly1762Ser). It was shown that the previously undescribed substitution c.5177G A (p.Gly1726Asp and another previously described mutation in this codon resulted in the replacement of glutamine with valine. This mutation causes the appearance of a less pronounced phenotype of AD. CONCLUSIONS: Based on the results of the examination of three Russian patients and analysis of clinical and radiographic parameters described in the literature, we reported that mutations in the FBN1 gene disrupted the amino acid sequence of the fifth like transforming growth factor-beta domain of fibrillin type 1. Importantly, these mutations are responsible for the occurrence of geleophysic dysplasia and acromicric dysplasia. However, the most severe clinical manifestations were observed in patients with mutations leading to the substitution of cysteine for arginine at the position of the polypeptide chain 1736. This may lead to affecting the transforming growth factor-beta signaling pathway.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
